(Q34748825)

4 August 2017

1 reference

title

New cholesterol guidelines, new treatment challenges (English)

1 reference

4 August 2017

James M McKenney

1

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 July 2002

1 reference

4 August 2017

1 reference

4 August 2017

volume

22

1 reference

4 August 2017

issue

7

1 reference

4 August 2017

page(s)

853-863

1 reference

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.11.853.33623

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.11.853.33623

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.11.853.33623

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.11.853.33623

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.11.853.33623

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.11.853.33623

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.11.853.33623

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.11.853.33623

Hypertriglyceridemia as a cardiovascular risk factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.11.853.33623

Triglycerides and atherogenic lipoproteins: rationale for lipid management

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.11.853.33623

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.11.853.33623

Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.11.853.33623

Statins: effective antiatherosclerotic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.11.853.33623

The evolving role of statins in the management of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.11.853.33623

Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.11.853.33623

Cerivastatin and reports of fatal rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.11.853.33623

Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.11.853.33623

Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.11.853.33623

Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.11.853.33623

Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.11.853.33623

Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.11.853.33623

Roles of PPARs in health and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.11.853.33623

Effective Lipid Modification by Partial Ileal Bypass Reduced Long-term Coronary Heart Disease Mortality and Morbidity: Five-Year Posttrial Follow-up Report From the POSCH

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.11.853.33623

10.1592/PHCO.22.11.853.33623

21 January 2018

Identifiers

DOI

1 reference

4 August 2017

1 reference